London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

LONDON, Ontario, June 10, 2024 (GLOBE NEWSWIRE) — London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024. LRP-661’s data highlights its superior […] Read The Rest at :